It was the last call he would ever make. Two floors down on the Cantor Fitzgerald floor, trader Jimmy DeBlase was on the phone to his wife, Marion, when a sound like thunder interrupted them.

Since ending in correction territory last week, Wall Street has rebounded, and Cantor Fitzgerald believes this rally could extend through to the end of the month. However, despite the potential ...

Belite Bio, Inc (NASDAQ:BLTE – Free Report) – Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Belite Bio in a research note issued on Tuesday ...

Arvinas, Inc. (NASDAQ:ARVN – Free Report) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th.Cantor ...

In a report released today, Andres Sheppard from Cantor Fitzgerald maintained a Buy rating on Ouster (OUST – Research Report), with a price target of $11.00. The company’s shares closed ...

Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $365.00. The company’s shares closed yesterday at $321.39.

Howard Lutnick is the U.S. Secretary of Commerce and the former CEO of Cantor Fitzgerald. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site ...

On Thursday, Cantor Fitzgerald reaffirmed its positive stance on Alumis Inc (NASDAQ: ALMS), maintaining an Overweight rating on the company’s shares. The stock, currently trading at $4.37 ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor Fitzgerald ...

Cantor Fitzgerald High Income Fd earns an Above Average Process Pillar rating. The most important driver of the rating is the parent firm's five-year risk-adjusted success ratio of 90%.